Overview

Subcutaneous Semaglutide in Systemic Scleroderma

Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This trial will study the safety and efficacy of subcutaneous semaglutide for the treatment of Systemic Sclerosis
Phase:
Phase 1
Details
Lead Sponsor:
Second Xiangya Hospital of Central South University
Treatments:
Semaglutide